MAM
VKTX icon

Meeder Asset Management’s Viking Therapeutics VKTX Stock Holding History

Meeder Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-155
Closed -$5.04K – 1052
2026
Q1 		$5.04K Buy
+155
New +$4.98K ﹤0.01% 816
2025
Q1 		– Sell
-42
Closed -$1.69K – 1057
2024
Q4 		$1.69K Sell
42
-1,916
-98% -$109K ﹤0.01% 889
2024
Q3 		$124K Buy
1,958
+1,156
+144% +$67.8K 0.01% 272
2024
Q2 		$42.5K Buy
802
+469
+141% +$30.7K ﹤0.01% 366
2024
Q1 		$27.3K Buy
+333
New +$14.8K ﹤0.01% 441
2020
Q4 		– Sell
-9,258
Closed -$53K – 2237
2020
Q3 		$53K Buy
+9,258
New +$63.7K ﹤0.01% 950
2019
Q1 		– Sell
-7,309
Closed -$56K – 1873
2018
Q4 		$56K Buy
7,309
+2,839
+64% +$33.9K 0.01% 785
2018
Q3 		$78K Buy
4,470
+4,334
+3,187% +$51.6K 0.01% 692
2018
Q2 		$1.29K Buy
+136
New +$905 ﹤0.01% 1461

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Meeder Asset Management's VKTX Position: Q2 2026 in Review

Meeder Asset Management sold out of Viking Therapeutics (VKTX) in Q2 2026, closing a stake of 155 shares — an estimated $5.04K sold.

Meeder Asset Management first reported a position in VKTX in Q2 2018 and held it in 9 quarters. The position peaked at $124K in Q3 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Meeder Asset Management reported no remaining Viking Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Meeder Asset Management sold 155 Viking Therapeutics shares in Q2 2026, an estimated $5.04K.
  • Meeder Asset Management first reported a position in Viking Therapeutics in Q2 2018 and held it in 9 quarters.
  • Meeder Asset Management's Viking Therapeutics position peaked at $124K in Q3 2024.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Meeder Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.